Kyntra Bio, Inc.

As of June 30, 2026, Kyntra Bio, Inc. carries a market capitalization of 487.40M, placing it among publicly traded companies globally. Its enterprise value stands at -723.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Kyntra Bio, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Kyntra Bio, Inc. has 4.05M shares outstanding.

As of June 30, 2026, Kyntra Bio, Inc. trades at a trailing price-to-earnings ratio of 0.15. The price-to-sales ratio is 6.04, and the price-to-book ratio stands at -0.93.

As of June 30, 2026, Kyntra Bio, Inc. maintains a current ratio of 2.69, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 131.26, measuring how efficiently the asset base is converted into earnings. The company generates approximately 986,744.68 in revenue per employee across its workforce of 81.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.19 indicates how many times Kyntra Bio, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Kyntra Bio, Inc. recorded an income tax benefit of -17,471.60 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -540.13M and 3.20B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Kyntra Bio, Inc. generated 80.67M in revenue and converted that into 3.20B in net income, yielding earnings per share of -133.49. EBITDA reached -875.36M, while operating income came in at -877.91M.

These figures are as of June 30, 2026. Total book value stands at -526.66M, with working capital of 1.06B providing operational flexibility.

Kyntra Bio, Inc. produced -664.85M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -157,244.40 in capital expenditures, free cash flow totaled -665.00M - equivalent to -164.35 per share.

Over the twelve months ended June 30, 2026, Kyntra Bio, Inc. posted a gross margin of 6.26, reflecting its pricing power and cost economics. The operating margin of -1,088.33 and net profit margin of 3,967.77 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -136.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 308.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Kyntra Bio, Inc. shareholders.

Kyntra Bio, Inc.'s most recent stock split took place on June 17, 2025 with a 25:1 split ratio.

As of June 30, 2026, Kyntra Bio, Inc. has an Altman Z-Score of -24.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.